Zhang Wenjie, Li Sumei, Long Jinlan, Xie Shufeng, Wang Minghui, Liu Han, Xu Zhenshu
Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, 29 Xinquan Rd, Fuzhou, 350001, China.
College of Chinese Traditional Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250013, China.
Exp Hematol Oncol. 2024 Apr 18;13(1):43. doi: 10.1186/s40164-024-00508-4.
Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancies (R/R BCM). Attempting to make CAR T-cells safer and more effective in treating R/R BCM, various novel engineered CAR T-cell agents are currently in the research and development or clinical trial stages. We have summarized here the latest reports on the novel CAR T-cell therapies for R/R BCM presented at the 2023 ASH Annual Meeting as well as the latest updates in related clinical trials.
嵌合抗原受体（CAR）是一种经过工程改造的融合蛋白，可将T细胞靶向肿瘤细胞的特定表面抗原，以产生有效的抗肿瘤反应。CAR T细胞疗法在复发/难治性B细胞恶性肿瘤（R/R BCM）的治疗中发挥着越来越重要的作用。为了使CAR T细胞在治疗R/R BCM时更安全、更有效，目前各种新型工程化CAR T细胞药物正处于研发或临床试验阶段。在此，我们总结了在2023年美国血液学会（ASH）年会上发表的关于R/R BCM新型CAR T细胞疗法的最新报告以及相关临床试验的最新进展。
